title: Stromal responses among common carcinomas correlated with clinicopathologic features.
abstract: OBJECTIVE
  We have previously characterized a tumor stroma expression signature in a subset of breast tumors that correlates with better clinical outcome. The purpose of this study is to determine whether this stromal signature, termed the "DTF fibroblast" (desmoid-type fibromatosis) signature, is specific to breast cancer or is a common stromal response found in different types of cancer.
  
  
  METHODS
  The DTF fibroblast signature was applied to gene expression profiles from five ovarian, five lung, two colon, and three prostate cancer expression microarray datasets. In addition, two different tissue microarrays of 204 ovarian tumors and 140 colon tumors were examined for the expression of previously characterized protein markers of DTF fibroblast signature. The DTF fibroblast stromal response was then correlated with clinicopathologic features.
  
  
  RESULTS
  The DTF fibroblast signature is robustly present in ovarian, lung, and colon carcinomas. Both expression microarray data and immunohistochemistry show that the subset of ovarian tumors with strong DTF fibroblast signature expression has statistically significant, worse survival outcomes. No reproducible survival differences were found in either the lung or the colon cancers. The prostate cancers failed to show a DTF fibroblast signature. Multivariant analysis showed that DTF fibroblast signature was significantly more prognostic than the proliferation status in ovarian carcinomas.
  
  
  CONCLUSIONS
  Our results suggest that the DTF fibroblast signature is a common tumor stroma signature in different types of cancer, including ovarian, lung, and colon carcinomas. Our findings provide further insight into the DTF fibroblast stromal responses across different types of carcinomas and their potential as prognostic and therapeutic targets.
authors.affiliation: Authors' Affiliations: Departments of Pathology and Medicine, Stanford University Medical Center; Department of Statistics, Stanford University, Stanford; Department of Medicine, Santa Clara Valley Medical Center, San Jose, California; and Department of Pathology, Hospital de la Santa Creu i Sant Pau, Institute of Biomedical Research (IIB Sant Pau), Autonomous University of Barcelona, Barcelona, Spain.
authors.forename: Julia L-Y
authors.initials: JL
authors.lastname: Chen
authors.forename: Iñigo
authors.initials: I
authors.lastname: Espinosa
authors.forename: Albert Y
authors.initials: AY
authors.lastname: Lin
authors.forename: Olivia Y-W
authors.initials: OY
authors.lastname: Liao
authors.forename: Matt
authors.initials: M
authors.lastname: van de Rijn
authors.forename: Robert B
authors.initials: RB
authors.lastname: West
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D049109:Cell Proliferation; D015331:Cohort Studies; D003110:Colonic Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology*; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology*; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor